Pharmaceuticals, Biotechnology & Life Sciences

Johnson & Johnson’s flat share performance, strong earnings outlook, and focus on market‑access, biosimilar pipeline and strategic M&A reveal how the company balances innovation with realistic growth.

Thermo Fisher Scientific’s strong growth, diversified life‑science tools and robust finances make it a top pick for investors seeking long‑term returns.

Takeda Pharmaceutical’s 2026 analyst outlook: a Hold rating amid steady growth, solid capital, and a diversified oncology‑CNS portfolio that keeps investors watching Japan’s pharma scene.

Grifols shares dip below €10.88 amid market volatility, facing a patent cliff for Gamunex‑C, new biosimilar plans, and strategic M&A opportunities to protect revenue and boost investor confidence.

WuXi AppTec earns a CDP “AA” climate & water‑security rating, boosting investor confidence and signaling robust ESG leadership in the biopharma sector.

Genmab’s EPCORE DLBCL‑1 results show improved PFS but no OS win, raising questions on pricing, reimbursement and the bispecific antibody market. Read the full analysis.

Johnson & Johnson’s February 2026 analyst shift: a buy‑to‑hold downgrade amid cost pressures, yet steady core strength and new mobile breast‑surgery simulator launch drive growth.

Genmab’s early 2026 trial of epcoritamab shows PFS, CR, and DOR gains in DLBCL, yet no OS benefit, prompting a Jyske Bank price hike and investor reassessment.

Short‑interest rises at WuXi AppTec, yet robust backlog, pipeline, and AI‑driven margin‑boosting plans keep its outlook strong.

Goldman Sachs lifts Roche Holding to neutral, citing stronger diagnostics-driven pricing and solid balance sheet amid looming patent cliffs – a fresh outlook for investors.